Hair $Scalp Disorders

Total Page：16

File Type：pdf, Size：1020Kb

FUNGAL INFECTIONS ( MYCOSES ) SUPERFICIAL MYCOSES - Pityriasis versicolor (Malassezia furfur) - Dermatophytosis (Tinea/Ringworm) DEEP MYCOSES MIXED MYCOSES - Candidiasis Pityriasis Versicolor Malassezia furfur (Pityrosporum - ovale - orbiculare) P. Versicolor Variable colour Hypopigmented Hyperpigmented -Superficial scaly plaques -Recurrence/ Relapse P. Versicolor Diagnosis - KOH exam -Culture Treatment Topical - Clotrimazole - Selenium sulphide - Zinc pyrithione Systemic Fluconazole - 400mg single dose Itraconazole - 100mg BD x 7 days Ketaconazole - 400mg single dose DERMATOPHYTIC INFECTIONS TINEA • Fungi imperfecti - Trichophyton - Epidermophyton - Microsporum •Keratinophillic •Sites : a) Skin - face, palm, soles, body folds b) Nail c) Hair TINEA CORPORIS TINEA MANUUM Diffuse hyperkeratosis Vesicular type Nail TINEA PEDIS Diffuse hyperkeratosis (Moccasin type) TINEA PEDIS Intertrigo TINEA PEDIS Vesicular type TINEA CRURIS Inguinal folds, buttock TINEA FACIEI TINEA FACIEI TINEA FACIEI TINEA CAPITIS Alopecia Hair easily pluckable Children Grey patch TINEA CAPITIS Black dot Alopecia Microsporum TINEA CAPITIS Kerion - T. mentagrophytes - Zooophillic - children TINEA CAPITIS Favus - T. schoenlenii - scaly (scutula) TINEA BARBAE TINEA UNGUIUM Nail plate TINEA INCOGNITO - Steroid modified tinea TINEA IMBRICATA - Trichophyton concentricum Diagnosis - Isolation - KOH exam (10%) - Culture Sabouraud;s Dextrose agar - Woods lamp Examination Treatment Topical a) Imidazole derivatives - Clotrimazole - Miconazole 1% cream/lotion - Oxiconazole b) Alkylamine derivatives Terbinafine1% cream/lotion Butenafine Ciclopiroxolamine c) Keratolytics Salicylic acid 3-6% Urea/ lactic acid - 10-20% • OTHERS - Tolnafatate cream - Whit field’s ointment - Undecenoic acid oint - Haloprogin cream SYSTEMIC : Drug of choice (griseofulvin) • Imidazoles - Fluconazole - Itraconazole - Ketoconazole • Terbinafine CURE - 6 weeks NAILS - 6 months or more THANK YOU .

Copy Link

Recommended publications

Fungal Infection
The Pocket Guide to Fungal Infection Second Edition Malcolm D. Richardson PhD, FIBiol, FRCPath Mycology Unit Department of Bacteriology and Immunology University of Helsinki Helsinki, Finland Elizabeth M. Johnson PhD Mycology Reference Laboratory Health Protection Agency Bristol, United Kingdom The Pocket Guide to Fungal Infection Second Edition To families and friends The Pocket Guide to Fungal Infection Second Edition Malcolm D. Richardson PhD, FIBiol, FRCPath Mycology Unit Department of Bacteriology and Immunology University of Helsinki Helsinki, Finland Elizabeth M. Johnson PhD Mycology Reference Laboratory Health Protection Agency Bristol, United Kingdom © 2005 Malcolm D. Richardson, Elizabeth M. Johnson Published by Blackwell Publishing Ltd Blackwell Publishing, Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia The right of the Authors to be identiﬁed as the Authors of this Work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. First edition published 2000 Reprinted 2000, 2002 Second Edition 2005 Library of Congress Cataloging-in-Publication Data Richardson, M. D. The pocket guide to fungal infection / Malcolm D. Richardson, Elizabeth M. Johnson. — 2nd ed. p. ; cm. Includes bibliographical references and index. ISBN-13: 978-1-4051-2218-4 ISBN-10: 1-4051-2218-8 1.
[Show full text]
Fungal Infections from Human and Animal Contact
Journal of Patient-Centered Research and Reviews Volume 4 Issue 2 Article 4 4-25-2017 Fungal Infections From Human and Animal Contact Dennis J. Baumgardner Follow this and additional works at: https://aurora.org/jpcrr Part of the Bacterial Infections and Mycoses Commons, Infectious Disease Commons, and the Skin and Connective Tissue Diseases Commons Recommended Citation Baumgardner DJ. Fungal infections from human and animal contact. J Patient Cent Res Rev. 2017;4:78-89. doi: 10.17294/2330-0698.1418 Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes, and the patient experience. REVIEW Fungal Infections From Human and Animal Contact Dennis J. Baumgardner, MD Aurora University of Wisconsin Medical Group, Aurora Health Care, Milwaukee, WI; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI; Center for Urban Population Health, Milwaukee, WI Abstract Fungal infections in humans resulting from human or animal contact are relatively uncommon, but they include a significant proportion of dermatophyte infections. Some of the most commonly encountered diseases of the integument are dermatomycoses. Human or animal contact may be the source of all types of tinea infections, occasional candidal infections, and some other types of superficial or deep fungal infections. This narrative review focuses on the epidemiology, clinical features, diagnosis and treatment of anthropophilic dermatophyte infections primarily found in North America.
[Show full text]
A Systematic Review of Diagnosis and Treatment Options for Tinea Imbricata
Int. J. Life Sci. Pharma Res. 2019 Oct; 9(4): (L) 28-33 ISSN 2250-0480 Review Article Dermatology International Journal of Life science and Pharma Research A SYSTEMATIC REVIEW OF DIAGNOSIS AND TREATMENT OPTIONS FOR TINEA IMBRICATA RANA ABDULAZEEM AL-BASSAM1, BASMAH SALEM AL AFARI 1 AND MANAL HASSAN MOHAMED SALEM2* 1Intern doctor, Dar Al Uloom University Riyadh, Saudi Arabia., 2Mater degree of dermatology,venereology and andrology , Doctor Abdulazeem Albassam Medical Group, Department of Dermatology, Riyadh, Saudi Arabia ABSTRACT Tinea imbricata is a cutaneous fungal disease and sometimes called (Tokelau). The causative agent is a dermatophyte known as Trichophyton concentricum. It is an endemic in developing countries particularly in South Pacific, India, Central and South America, as well as Mexico. It is generally observed in people with poor living conditions and poor personal hygiene. Predisposing factors are hot weather, humidity, and host immunity in addition to genetic factors. The patients usually presented with concentric or lamellar skin lesions. The aim of this review is to highlight important information about microbial, clinical and therapeutic aspects of tinea imbricta. In this review, we search the literature to identify articles talking different aspects of tinea imbricta. The electronic search was performed in four databases to identify eligible articles in the literature. Electronic databases were searched including MEDLINE and EMBASE using PubMed search engine. In addition, Cochrane library and ovid was searched. The titles and abstracts of the resulted articles were screened to identify eligible studies. Based on the primary screening results the irrelevant studies, duplicated and reviews were excluded. Tinea imbricta is found to be endemic in 3 main geographical regions, Southwest Pacific, Southeast Asia, and Central and South America.
[Show full text]
Tinea Capitis
TPGC01.qxd 1/5/06 1:15 PM Page 4 Dermatophytosis Tinea capitis Tinea capitis due to Trichophyton tonsurans. Kerion due to Trichophyton verrucosum. Definition Tinea capitis describes infection of the scalp and hair with a dermatophyte. Geographical distribution World-wide, but more common in Africa, Asia and southern and eastern Europe, occurring mainly in prepubescent children. Increasing incidence. 4 TPGC01.qxd 1/5/06 1:15 PM Page 5 Dermatophytosis Hair infected by Microsporum gyseum showing large-spored ecothrix invasion. Macroconidia of Microsporum canis. Causal organisms and habitat • Several Trichophyton spp. and Microsporum spp. • Zoophilic M. canis (cats and dogs) is common in western Europe. • Anthropophilic T. violaceum is predominant in eastern and southern Europe and north Africa. • Anthropophilic T. tonsurans is increasing in prevalence, especially in North America. 5 TPGC01.qxd 1/5/06 1:15 PM Page 6 Dermatophytosis Microsporum canis in culture. • Anthropophilic species can be contagious and endemic. • T. schoenleinii causes favus. Clinical manifestations • Mild scaling lesions to widespread alopecia. • Kerion: highly inflammatory, suppurating lesion caused by zoophilic dermatophytes. • Black dot appearance seen with ectothrix hair invasion. • Favus is a distinctive infection with grey, crusting lesions. • Asymptomatic carrier state recognized, may promote spread of infection. • T. tonsurans and T. violaceum – most commonly implicated in the carrier state. • Minimal inflammatory response. • Low spore numbers. • Topical treatment
[Show full text]
Antifungals, Oral
Antifungals, Oral Therapeutic Class Review (TCR) July 13, 2018 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. July 2018 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2018 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer FDA-Approved Indication(s) for oral use clotrimazole generic .
[Show full text]
Oral Antifungals Month/Year of Review: July 2015 Date of Last
© Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluation: Oral Antifungals Month/Year of Review: July 2015 Date of Last Review: March 2013 New Drug: isavuconazole (a.k.a. isavunconazonium sulfate) Brand Name (Manufacturer): Cresemba™ (Astellas Pharma US, Inc.) Current Status of PDL Class: See Appendix 1. Dossier Received: Yes1 Research Questions: Is there any new evidence of effectiveness or safety for oral antifungals since the last review that would change current PDL or prior authorization recommendations? Is there evidence of superior clinical cure rates or morbidity rates for invasive aspergillosis and invasive mucormycosis for isavuconazole over currently available oral antifungals? Is there evidence of superior safety or tolerability of isavuconazole over currently available oral antifungals? • Is there evidence of superior effectiveness or safety of isavuconazole for invasive aspergillosis and invasive mucormycosis in specific subpopulations? Conclusions: There is low level evidence that griseofulvin has lower mycological cure rates and higher relapse rates than terbinafine and itraconazole for adult 1 onychomycosis.2 There is high level evidence that terbinafine has more complete cure rates than itraconazole (55% vs. 26%) for adult onychomycosis caused by dermatophyte with similar discontinuation rates for both drugs.2 There is low
[Show full text]
Therapies for Common Cutaneous Fungal Infections
MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
[Show full text]
Therapies for Common Cutaneous Fungal Infections
MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
[Show full text]
Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
[Show full text]
Tinea Manuum Misdiagnosed As Psoriasis Vulgaris: a Case of Tinea Incognito
Our Dermatology Online Case Report TTineainea mmanuumanuum mmisdiagnosedisdiagnosed aass ppsoriasissoriasis vvulgaris:ulgaris: AA case case ooff ttineainea iincognitoncognito Funda Tamer1, Mehmet Eren Yuksel2 1Department of Dermatology, Medical Park Hospital, Ankara, Turkey, 2Department of General Surgery, Devrek State Hospital, Zonguldak, Turkey Corresponding author: Dr. Funda Tamer, E-mail: [email protected] ABSTRACT Tinea incognito is a dermatophyte infection with altered clinical appearance which is usually caused by the use of immunosuppressive agents such as topical corticosteroids. Hereby, we present a 59-year-old Caucasian male patient with tinea manuum on the dorsum of his left hand. The lesion was formerly misdiagnosed as psoriasis vulgaris and treated with topical corticosteroids. However, the symptoms were worsened. Moreover, new papules and pustules appeared within the lesion. The past medical history was remarkable for psoriasis vulgaris and he had an erythematous and squamous plaque on his lower back resembling psoriasis vulgaris. In order to reach a definitive diagnosis, the skin lesion on the dorsum of the patient’s left hand was examined by light microscopy after the application of 10% potassium hydroxide solution. Detection of septate hyphae confirmed dermatophytosis. The lesion was completely healed with oral terbinafine 250 mg daily for four weeks. Dermatophyte infections in early stages may be misdiagnosed as psoriasis vulgaris and thus, prolonged use of corticosteroids can lead to tinea incognito. Therefore, cutaneous lesions unresponsive to topical corticosteroid treatment should be evaluated with microscopic examination and fungal culture to confirm a suspected dermatophyte infection. Past medical history can provide useful information but a complete dermatological examination should be performed before the final diagnosis is made.
[Show full text]
Med Chem 401: Mycology Mycology
Med Chem 401: Mycology (www.doctorfungus.org) Mycology is the Study of Fungi (Monera, Protoctista, Fungi, Plantae, Animalia). Fungi are eukaryotic cells and as such contain nuclei, mitochondria, ER, golgi, 80S ribosomes, etc., bound by a plasma membrane. Note that fungal cell membranes contain ergosterol rather than cholesterol. Mycology In addition, fungi possess a rigid cell wall containing chitin, glucans and other sugar polymers. Mycology Fungi are classified as •Yeasts - round/oval cells that divide by budding •Moulds - tubular structures (hyphae) that grow by longitudinal extension and branching. A mass of hyphae is called a mycelium Diseases Caused by Fungi Fungal infections in normal healthy adults are confined to conditions such as mucosal candidiasis (e.g., thrush) and dermatophyte (tinea) skin infections (e.g., athlete's foot). However, in the immunocompromised host, a variety of normally mild or nonpathogenic fungi can cause potentially fatal infections. Diseases Caused by Fungi Fungal infections are classified depending on the degree of tissue involvement and mode of entry: 1. Superficial - localized to the skin, hair and nails. 2. Subcutaneous - infection confined to the dermis, subcutaneous tissue, or adjacent structures. 3. Systemic - deep infections of the internal organs. 4. Opportunistic - cause infection only in the immunocompromised. 1. Superficial Mycoses The Dermatophytes The dermatophytes are not a specific fungus, but rather a short-hand label for three genera of fungi that commonly cause skin disease (tinea). •Epidermophyton spp. •tinea capitis •tinea barbae •Trichophyton spp. •tinea pedis •Microsporum spp. •tinea cruis 1. Superficial Mycoses The Dermatophytes Tinea pedis “athletes foot” Tinea capitis Epidermophyton spp. Microsporum spp. 1.
[Show full text]
Fungal Group Fungal Disease Source Guidelines
Fungal Fungal disease Source Guidelines Relevant articles Group ESCMID guideline for the diagnosis and management of Candida diseases 2012: 1. Developing European guidelines in clinical microbiology and infectious diseases 2. Diagnostic procedures 3. Non-neutropenic adult patients 4. Prevention and management of Candida diseases ESCMID invasive infections in neonates and children caused by Candida spp 5. Adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT) 6. Patients with HIV infection or AIDS Candidaemia and IDSA clinical practice guidelines 2016 IDSA invasive candidiasis ISPD ISPD guidelines/recommendations Candida peritonitis Special article: reducing the risks of peritoneal dialysis-related infections Invasive IDSA IDSA clinical practice guidelines 2010 WHO management guidelines WHO Cryptococcal meningitis Guidelines for the prevention and AIDSinfo treatment of opportunistic infections in HIV-infected Adults and adolescents Southern Guideline for the prevention, African diagnosis and management of HIV cryptococcal meningitis among HIV- clinicians infection persons: 2013 update society IDSA Clinical practice guidelines 2007 IDSA Histoplasmosis disseminated Guidelines for the prevention and treatment of opportunistic infections in AIDSinfo HIV-infected Adults and adolescents IDSA Clinical practice guidelines 2007 Histoplasmosis IDSA acute pulmonary AIDSinfo Guidelines for the prevention and treatment of opportunistic infections in HIV-infected Adults and adolescents Invasive IDSA Clinical
[Show full text]